Alpa Laboratories Ltd.
Snapshot View

49.70 -0.50 ▼-1.0%

26 July 2021, 04:00:00 P.M.
Volume: 8,835

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.alpalabs.com/www.alpalabs.in
Financial Indicators
Market Cap 105.62 Cr.
Earnings per share (EPS) 3.44 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 14.57 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 51.16 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.98 Calculated using Price: 50.20
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 2.10 Cr. 21,040,600 Shares
FaceValue 10
Company Profile

Alpa Laboratories, incorporated in 1988, is engaged in the business of manufacturing pharmaceutical products. In 1967, the company started its journey as a partnership concern with Purushottam R Patel, M S Chawla and Pravin C Shah as the founding partners. Later on March 18, 1988 the company became a private limited company and a decade later it became a public limited enterprise.

The company manufactures a spectrum of products such as ethical drugs, generic drugs, over the counter drugs (OTC) and veterinary products. These products are manufactured in various dosage forms such as injectables (vials/ampoules both liquid and dry), tablets, capsules, eye/ear drops, ointment and creams. The company markets these products under the trademark 'Alpa'.

The company manufactures formulations for other major pharmaceutical companies namely Cipla, Zydus Cadila, Lupin, Glenmark, Genom, Biotech Jenburkt etc. Alpa Laboratories exports a wide range of products to countries such as Philippines, Iran, Iraq, Sierra Leon, Madagascar, Kenya, Liberia, Puerto Rico, Haiti, Sudan, Ghana, Nigeria, Sri Lanka, etc.

Products

The company manufactures a wide range of drugs and formulation for human use. These drugs cater to therapeutic segments such as antibacterial, anti-inflammatory, anti-allergic, anti-histaminics and anti-infective are among others. It manufactures products such as Alquin, optamycin, Amoxycillin capsules and many more

Alpha Labs also manufactures veterinary products such as diphen and grotax-250 among others.

Milestones

1988- Alpa Laboratories was incorporated as private limited company.

1997- The company set up a manufacturing facility at Pigdamber, Indore.

1998- It was converted into public limited enterprise

1999- The company started of commercial production of the unit.

2001- Alpha received WHO GMP Certification for its manufacturing facilities. It entered into an agreement with Plethico Pharmaceuticals for contract manufacturing. The company’s Pigdamber unit were certified as WHO GMP compliant by SGS-ICS Belgium for the period 2001-02.

2003- The Pigdamber unit received ISO 9001: 2000 certification. The same year company started exporting its veterinary products. It registered 7 veterinary products in Sudan.

2006- The company established veterinary division with a new face and ethical promotion of its veterinary products launched in 5 states. Alpha also launched Ethical division for its human products.

2007- Alpa Laboratories collaborated with Vhermann Pharmaceutical Inc Philippines for distribution of its products international marketing

Future plans

Alpa Laboratories is engaged in developing new products and services to strengthen its presence. The company also plans to explore untapped markets.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.00%
1 Week
-2.17%
1 Month
-8.22%
3 Month
-26.10%
6 Month
+37.48%
1 Year
+140.10%
2 Year
+188.12%
5 Year
+41.80%
7 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -5.84 -1.60 7.61 2.68 2.92 1.03 1.86
Return on Capital Employed (%) -2.54 -0.89 9.61 6.59 5.47 3.26 3.09
Return on Assets (%) -4.07 -1.10 4.99 1.86 2.29 0.84 1.54

Balance Sheet View Details

Particulars 7 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 88 87 93 95 98 98 100
Non Curr. Liab. 6 0 1 0 0 0 -1
Curr. Liab. 32 41 52 30 23 22 21
Minority Int.
Equity & Liab. 127 128 146 125 121 121 120
Non Curr. Assets 74 16 27 20 23 27 25
Curr. Assets 53 113 119 105 98 94 95
Misc. Exp. not W/O
Total Assets 127 128 146 125 121 121 120

Profit Loss View Details

Particulars 7 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 57 57 54 63 63 78 86
Other Income 1 3 6 5 5 5 3
Total Income 57 61 59 69 68 83 89
Total Expenditure -51 -55 -47 -56 -59 -77 -83
PBIDT 6 6 12 12 9 6 6
Interest -2 -2 -1 -2 -1 -1 0
Depreciation -9 -6 -1 -3 -3 -3 -3
Taxation 0 1 -3 -3 -2 -2 -1
Exceptional Items -1 -2
PAT -5 -1 7 3 3 1 2

Cash Flow View Details

Particulars 7 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 8 -2 -22 17 -13 -1 18
Cash Fr. Inv. -2 37 -8 -2 -11 -15 -11
Cash Fr. Finan. 4 7 -6 -15 9 -5 -1
Net Change 10 42 -36 0 -15 -20 5
Cash & Cash Eqvt 10 53 17 37 21 1 6

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 56.66 56.66 56.66 56.66 56.66 56.66 56.66 56.66 56.66
Public 43.34 43.34 43.34 43.34 43.34 43.34 43.34 43.34 43.34
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 12 Jul 2021
Closure of Trading Window
Intimation of Closure of Trading Window.
Tue, 06 Jul 2021
Shareholding for the Period Ended June 30 2021
Alpa Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Mon, 05 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- ADITYA SINGH
Designation :- Company Secretary and Compliance Officer

Technical Scans View Details

Fri, 23 Jul 2021
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 703.40 +1.4%
Divi's Laboratories Ltd. 128,088.59 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,411.25 -0.2%
Cipla Ltd. 76,510.04 950.55 +0.3%
Cadila Healthcare Ltd. 62,965.29 605.55 -1.6%
Aurobindo Pharma Ltd. 56,484.48 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. 56,291.69 4,100.95 +4.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.81 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 4,100.95 +4.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.17 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 4,100.95 +4.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%